Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 212

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Kazda, Christof M., Ding, Ying, Kelly, Ronan P., Garhyan, Parag, Shi, Chunxue, Lim, Chay Ngee, Fu, Haoda, Watson, David E., Lewin, Andrew J., Landschulz, William H., Deeg, Mark A., Moller, David E., Hardy, Thomas A.·2016·Diabetes Care

Abstract

OBJECTIVE: Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: The efficacy (HbA1c and glucose) and safety (serum aminotransferase) of once-daily oral administration of LY2409021 was assessed in two double-blind studies. Phase 2a study patients were randomized to 10, 30, or 60 mg of LY2409021 or placebo for 12 weeks. Phase 2b study patients were randomized to 2.5, 10, or 20 mg LY2409021 or placebo for 24 weeks. RESULTS: LY2409021 produced reductions in HbA1c that were significantly different from placebo over both 12 and 24 weeks. After 12 weeks, least squares (LS) mean change from baseline in HbA1c was –0.83% (10 mg), –0.65% (30 mg), and –0.66% (60 mg) (all P < 0.05) vs. placebo, 0.11%. After 24 weeks, LS mean change from baseline in HbA1c was –0.45% (2.5 mg), –0.78% (10 mg, P < 0.05), –0.92% (20 mg, P < 0.05), and –0.15% with placebo. Increases in serum aminotransferase, fasting glucagon, and total fasting glucagon-like peptide-1 (GLP-1) were observed; levels returned to baseline after drug washout. Fasting glucose was also lowered with LY2409021 at doses associated with only modest increases in aminotransferases (mean increase in alanine aminotransferase [ALT] ≤10 units/L). The incidence of hypoglycemia in the LY2409021 groups was not statistically different from placebo. CONCLUSIONS: In patients with type 2 diabetes, glucagon receptor antagonist treatment significantly lowered HbA1c and glucose levels with good overall tolerability and a low risk for hypoglycemia. Modest, reversible increases in serum aminotransferases were observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc15-1643

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 29

  1. Woerle, 2006, Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes, Am J Physiol Endocrinol Metab, 290, E67, 10.1152/ajpendo.00529.2004 · DOI
  2. Sloop, 2005, Glucagon as a target for the treatment of type 2 diabetes, Expert Opin Ther Targets, 9, 593, 10.1517/14728222.9.3.593 · DOI
  3. Hollander, 1982, Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man, Diabetes, 31, 489, 10.2337/diab.31.6.489 · DOI
  4. Ward, 1984, Prolonged infusion of somatostatin with glucagon replacement increases plasma glucose and glucose turnover in man, J Clin Endocrinol Metab, 58, 449, 10.1210/jcem-58-3-449 · DOI
  5. Dunning, 2007, The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications, Endocr Rev, 28, 253, 10.1210/er.2006-0026 · DOI · Paper page
  6. Gastaldelli, 2000, Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study, Diabetes, 49, 1367, 10.2337/diabetes.49.8.1367 · DOI · Paper page
  7. Shah, 2000, Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus, J Clin Endocrinol Metab, 85, 4053
  8. Bagger, 2011, Glucagon antagonism as a potential therapeutic target in type 2 diabetes, Diabetes Obes Metab, 13, 965, 10.1111/j.1463-1326.2011.01427.x · DOI
  9. Tham, 2011, The glucagon receptor antagonist LY2409021 attenuates increases in hepatic glucose output (HGO) and blood glucose during hyperglucagonemia in healthy male patients (Abstract 416-PP), Diabetes, 60, A115
  10. Kelly, 2015, Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes, Diabetes Obes Metab, 17, 414, 10.1111/dom.12446 · DOI · Paper page
  11. Kelly, 2015, Glucagon receptor antibody LY2786890 reduced glucose levels in type 2 diabetes mellitus patients (Abstract 106-LB), Diabetes, 64, LB27
  12. Engel, 2011, Efficacy and tolerability of MK-0893, a glucagon receptor antagonist (GRA), in patients with type 2 diabetes (T2DM) (Abstract 309-OR), Diabetes, 60, A85
  13. Ruddy, 2011, Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy of a glucagon receptor antagonist, MK-0893, in type 2 diabetes (T2DM) (Abstract 311-OR), Diabetes, 60, A85
  14. Kazierad, 2015, Pharmacokinetics (PK) and pharmacodynamics (PD) of PF-06291874 (PF), a glucagon receptor antagonist, in subjects with T2DM (Abstract 1202-P), Diabetes, 64, A310
  15. Vajda, 2015, Pharmacokinetics and pharmacodynamics of the glucagon receptor antagonist LGD-6972 in a multi-dose clinical trial (Abstract 1193-P), Diabetes, 64, A308
  16. Morgan, 2014, ISIS-GCGRRX, an antisense glucagon receptor antagonist, caused rapid, robust, and sustained improvements in glycemic control without changes in BW, BP, lipids, or hypoglycemia in T2DM patients on stable metformin therapy (Abstract 109-LB), Diabetes, 63, LB28
  17. Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
  18. Sloan, 2012, A novel high-sensitivity electrochemiluminescence (ECL) sandwich immunoassay for the specific quantitative measurement of plasma glucagon, Clin Biochem, 45, 1640, 10.1016/j.clinbiochem.2012.07.111 · DOI
  19. Petersen, 2001, Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans, Diabetologia, 44, 2018, 10.1007/s001250100006 · DOI · Paper page
  20. Whalley, 2011, Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells, J Endocrinol, 211, 99, 10.1530/JOE-11-0094 · DOI · Paper page
  21. Longuet, 2013, Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor, Diabetes, 62, 1196, 10.2337/db11-1605 · DOI · Paper page
  22. Ali, 2011, Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis, J Clin Invest, 121, 1917, 10.1172/JCI43615 · DOI
  23. Gu, 2010, Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor, Am J Physiol Endocrinol Metab, 299, E624, 10.1152/ajpendo.00102.2010 · DOI
  24. Lefèbvre, 2015, Inhibiting or antagonizing glucagon: making progress in diabetes care, Diabetes Obes Metab, 17, 720, 10.1111/dom.12480 · DOI
  25. Yu, 2011, Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice, PLoS One, 6, e23397, 10.1371/journal.pone.0023397 · DOI
  26. Sinclair, 2008, Glucagon receptor signaling is essential for control of murine hepatocyte survival, Gastroenterology, 135, 2096, 10.1053/j.gastro.2008.07.075 · DOI
  27. Liang, 2004, Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice, Diabetes, 53, 410, 10.2337/diabetes.53.2.410 · DOI · Paper page
  28. Hancock, 2010, Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice, Mol Endocrinol, 24, 1605, 10.1210/me.2010-0120 · DOI
  29. Sloop, 2004, Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors, J Clin Invest, 113, 1571, 10.1172/JCI20911 · doi:10.1172/jci20911 · Paper page

Cited by

See all 212

Metadata

Authors
Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., Deeg, M. A., Moller, D. E., & Hardy, T. A.
Venue
Diabetes Care
Published
2015-12-17
Volume
39
Issue
7
Pages
1241-1249
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2207556001
Cited by
212
References
6
FWCI
16.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. https://app.cochat.ai/papers/10.2337/dc15-1643
The paper
Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., Deeg, M. A., Moller, D. E., & Hardy, T. A. (2016). Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care. https://doi.org/10.2337/dc15-1643

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.